Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Unknown × NSCLC × Axitinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Renal Cell 4 Neoplasm Metastasis 2 Relapsed Pediatric Solid Tumor 1 Neuroendocrine Tumors 1 NSCLC 1 Melanoma 1 Liver Neoplasms 1 Kidney Neoplasms 1 Carcinoma, Non-Small-Cell Lung 1 Carcinoma 1 Biliary Tract Neoplasms 1

Interventions

Gefitinib 5 icotinib 4 apatinib 3 anlotinib 3 Pemetrexed 3 Erlotinib Hydrochloride 3 Docetaxel 3 osimertinib 2 dacomitinib 2 camrelizumab 2 aflutinib 2 Thalidomide 2 Drug Therapy 2 Carboplatin 2 Afatinib 2 spartalizumab 1 pembrolizumab 1 nimotuzumab 1 envafolimab 1 Vinorelbine 1 Tyrosine Kinase Inhibitors 1 S 1 (combination) 1 Radiosurgery 1 Radiofrequency Ablation 1 Immune Checkpoint Inhibitors 1 Cisplatin 1 Bevacizumab 1 Axitinib 1 Aspirin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06020352 2023-08-31

The Efficacy and Safety of KN046 Combined With Axitinib

Shanghai Pulmonary Hospital, Shanghai, China

Phase 2/3 Unknown

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡